Key facts
- It has raised $2.4M across 1 recorded rounds; the latest was Seed Round ($1.3M) in Jan 2026.
- Notable investors include Creative Destruction Lab, National Institutes of Health, University of California, CONNECT (San Diego), Good Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Navega Therapeutics
Funding rounds
1 roundsAbout Navega Therapeutics
Developer of gene therapies designed to treat chronic pain and tackle the opioid epidemic. The company's therapies target pain that is non-addictive, particular, and long-lasting, enabling healthcare practitioners to offer alternative treatments for chronic pain and reduce the amount of pain felt in one particular location.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Employees
- 7
- Website
- navegatx.com/
- Ownership
- Privately Held (backing)
Navega Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Navega Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Navega Therapeutics in its N-PORT filings yet. We sweep new filings monthly.